X Facebook LinkedIn WhatsApp Press Releases Any (-) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2024 February 20, 2024 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy January 17, 2024 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis January 8, 2024 argenx Highlights 2024 Strategic Priorities January 2, 2024 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference Pagination First page « First Previous page ‹ Previous Page 1 Current page 2